PTO/SB06s (08-43)
Approved for use through 07/21/2000 M6 695-4031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless for contains a valid officer foundation.

Remove

	Application Numb
	Filing Date
	First Named Inver
(Not for submission under 37 CFR 1.99)	Art Unit
(Not for submission under 37 CFR 1.99)	F

Application Number		10517847		
Filing Date		2004-12-14		
First Named Inventor K. Ka		miyama		
Art Unit		tba		
Examiner Name tba				
Attorney Docket Number		3082 US0P		

					U.S.I	PAIENIS			Hemove		
Examiner Initial*	Cite No	Patent Number	Issue Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n informati	on pl	ease click the	Add button.		Add		
			U.S.P	ATENT AF	PLIC	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publicatio Date	n	of sited Dogument		Relev	s,Columns,Lin ant Passages es Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication ci	itatio	n information p	lease click the Ad	d butto			
				FOREIGN	PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		ind ode4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colum where Releva Passages or Figures Appe	ant Relevant	T5
	1	WO 02/04448	us			2002-01-17	Neotherapeutics, I	nc.			
	2	WO 02/04452	US			2002-01-17	Neotherapeutics, I	nc.			
	3	WO 02/096910	us			2002-12-05	Coulter Pharmacel Inc.	utical,			

U.S.PATENTS

	0.14.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1						
EFS-Web Receipt date: 08/28/200	Application Number		10517847				
INFORMATION BIGGI COURT	Filing Date		2004-12-14				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	K. Ka	. Kamiyama				
(Not for submission under 37 CFR 1.99)	Art Unit		tba				
(not for outsimosion under or or it noo,	Examiner Name	tba					
	Attorney Docket Number		3082 US0P				

If you wis	h to a	ld additional Foreign Patent Document ci	tation information please click the Add button	Add			
		NON-PATENT	LITERATURE DOCUMENTS	Remove			
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	HIGHFIELD, J., et al., "Preparative, Physico-Chemical and Cytotoxicity Studies of Prodrugs Activated in Hypoxia to give Metal-Binding Analogues of Bleomycin", J. Chem. Soc., Perkin Trans., (1999), pages 2343-2351						
	2 OIRY, J., et al., "NAC/MEA Conjugate: A New Potent Antioxidant which Increases the GSH Level in Various Cell Lines", Bioorganic & Medicinal Chemistry Letters 11, (2001), pages 1189-1191						
If you wis	h to ac	ld additional non-patent literature docum	ent citation information please click the Add b	utton Add			
		EXA	MINER SIGNATURE				
Examiner	Examiner Signature /Taofiq Solola/ Date Considered 06/01/2008						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must peed the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./

English language translation is attached.

FS-Web Receipt date: 08/28/200		Application Number		10517847	10517847			
	Filing Date		2004-12-14	2004-12-14				
INFORMATION	First Named Inventor K. K		K. Kamiyama	Kamiyama				
	BY APPLICANT under 37 CFR 1.99)	Art Unit	t					
(Not for submission	runder 57 Or K 1.55)	Examiner Name		tba				
		Attorney Docket 1	Numbe	r 3082 US0P	3082 US0P			
		CERTIFICATION	STATE	MENT				
Please see 37 CFR 1	.97 and 1.98 to make the	appropriate selectio	n(s):					
from a foreign p		oart foreign applicat			first cited in any communication months prior to the filing of the			
OR								
OK .	\							
foreign patent of after making rea any individual de	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
See attached cer	rtification statement.	X						
Fee set forth in 3	7 CFR 1.17 (p) has been	submitted he ewith.						
✓ None			/					
A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.								
Signature	/Elaine Ramesh/		Date (YYYY-MM-DD)				
Name/Print	Elaine M. Ramesh		Regist	ration Number	43,032			
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments not be among not among the difference of the process.								

This collection of information is reguired by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the DSPTO to process) an application. Confidentiality is governed by 15.5. 1.22 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief-Normation Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act please be advised that: (1) the general authority for the collection of this information is 35 U.S. C. 2(b/2); (2) furnishing the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you'n this form will be subject to the following routine uses:

- The information on this nam will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act equires disclosure of these records.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribugal, including disclosures to opposing counsel in the course of settlement necotiations.
- A record in this system of records may be disclosed, as a royfine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the hocord.
- 4. A record in this system of records may be disclosed as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, purequant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records gray be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of secords may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an insection of records conducted by GSA as part of that agency's responsibility to recomment improvements infecords management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other pleavant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about ighiriduduals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after hither publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fled in an application which became adandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - Afecord from this system of records may be disclosed, as a routine use, to a Federal, State, or local aw enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.